特别提示 股票代码：688321 股票简称：微芯生物 深圳微芯生物科技股份有限公司 2024 年度向特定对象发行 A 股股票 上市公告书 保荐机构（主承销商） （深圳市福田区福田街道福华一路119号安信金融大厦） 二〇二六年三月 本次发行对象认购本次发行的股票自发行结束之日起 6 个月内不得转让。法 律法规对限售期另有规定的，依其规定。本次发行对象所取得公司发行的股份因 公司分配股票股利、资本公积金转增等形式所衍生取得的股份亦应遵守上述股份 锁定安排。上述限售期届满后，该等股份的转让和交易将根据届时有效的法律法 规及中国证监会、上海证券交易所的有关规定执行。法律、法规对限售期另有规 定的，依其规定。 | 特别提示 2 | | --- | | 目录 3 | | 释义 4 | | 第一节 本次发行的基本情况 5 | | 一、发行人基本情况 5 | | 二、本次新增股份发行情况 6 | | 第二节 本次新增股票上市情况 24 | | 一、新增股份上市批准情况 24 | | 二、新增股份的证券简称、证券代码和上市地点 24 | | 三、新增股份的上市时间 24 | | 四、新增股份的限售安排 24 | | 第三节 本 ...

国投证券股份有限公司 关于深圳微芯生物科技股份有限公司 2024 年度向特定对象发行 A 股股票 之 上市保荐书 保荐机构（主承销商） 二〇二六年三月 深圳微芯生物科技股份有限公司 上市保荐书 上海证券交易所： 国投证券股份有限公司（以下简称"国投证券"或"保荐机构"）接受深圳 微芯生物科技股份有限公司（以下简称"微芯生物"、"发行人"、"上市公司" 或"公司"）的委托，担任其 2024 年度向特定对象发行 A 股股票的保荐人。 保荐机构及保荐代表人根据《中华人民共和国公司法》《中华人民共和国证 券法》《证券发行上市保荐业务管理办法》《上市公司证券发行注册管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司证券发行与 承销业务实施细则》等有关法律、行政法规和中国证券监督管理委员会、上海证 券交易所的规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则和行业自 律规范出具上市保荐书，并保证所出具文件真实、准确、完整。 本上市保荐书如无特别说明，相关用语与《深圳微芯生物科技股份有限公司 2024 年度向特定对象发行 A 股股票募集说明书》中相同的含义。 3-2-1 | 目 录 2 | | -- ...

国投证券股份有限公司 关于深圳微芯生物科技股份有限公司 使用部分暂时闲置募集资金进行现金管理及募集资金余 额以协定存款方式存放的核查意见 国投证券股份有限公司(以下简称"国投证券"或"保荐机构")作为深圳 微芯生物科技股份有限公司(以下简称"微芯生物"或"公司")2024年度向 特定对象发行 A 股股票持续督导的保荐机构,根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律 监管指引第1号 -- 规范运作》等有关法律、法规的规定以及《深圳微芯生物科 技股份有限公司募集资金管理制度》的相关规定,对公司使用部分暂时闲置募集 资金进行现金管理及募集资金余额以协定存款方式存放事项进行了认真、审慎的 核查,并发表意见如下: 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意深圳微芯生物科技股份有限 公司向特定对象发行股票注册的批复》(证监许可〔2025〕2604 号),深圳微 芯生物科技股份有限公司(以下简称"公司")向特定对象发行人民币普通股 (A 股) 35,133,136 股,每股面值人民币 1.00 元,发行价格为 27.04元/股,上 述募集资金总 ...

使用部分募集资金向全资子公司实缴出资、增资及提供借 款以实施募投项目的核查意见 国投证券股份有限公司(以下简称"国投证券"或"保荐机构")作为深圳 微芯生物科技股份有限公司(以下简称"微芯生物"或"公司")2024年度向 特定对象发行 A 股股票持续督导的保荐机构,根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律 监管指引第1号 -- 规范运作》等有关法律、法规的规定以及《深圳微芯生物科 技股份有限公司募集资金管理制度》的相关规定,对公司使用部分募集资金向全 资子公司实缴出资、增资及提供借款以实施募投项目事项进行了认真、审慎的核 查,并发表意见如下: 国投证券股份有限公司 关于深圳微芯生物科技股份有限公司 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意深圳微芯生物科技股份有限 公司向特定对象发行股票注册的批复》(证监许可〔2025〕2604 号),深圳微 芯生物科技股份有限公司(以下简称"公司")向特定对象发行人民币普通股 (A 股) 35,133,136 股,每股面值人民币 1.00 元,发行价格为 27.04元/股,上 述募集资金总额人 ...

证券代码：688321 证券简称：微芯生物 公告编号：2026-019 深圳微芯生物科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理及募集资金 余额以协定存款方式存放的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳微芯生物科技股份有限公司（以下简称"公司"或"微芯生物"）于 2026 年 3 月 3 日召开了第三届董事会第二十三次会议，审议通过了《关于使用部分暂 时闲置募集资金进行现金管理及募集资金余额以协定存款方式存放的议案》，在 不影响公司募集资金投资计划正常进行的前提下，使用最高不超过人民币 6.6 亿 元（含本数）的暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好、 有保本约定的投资产品（包括但不限于结构性存款、通知存款、定期存款、大额 存单、收益凭证等），并将募集资金余额以协定存款方式存放，期限不超过 12 个月，自董事会审议通过之日起 12 个月内有效。在前述额度及期限范围内，公 司可以循环滚动使用。公司董事会授权公司董事长及财务人员根据实际情况办理 相关事宜并签署相关文件。保荐机 ...

证券代码：688321 证券简称：微芯生物 公告编号：2026-018 深圳微芯生物科技股份有限公司 关于使用部分募集资金向全资子公司实缴出资、增资及提供 借款以实施募投项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳微芯生物科技股份有限公司（以下简称"公司"）于 2026 年 3 月 3 日 召开第三届董事会第二十三次会议，审议通过《关于使用部分募集资金向全资子 公司实缴出资、增资及提供借款以实施募投项目的议案》，同意公司使用 3,080 万元的募集资金向全资子公司彭州微芯药业有限公司（以下简称"彭州微芯"） 实缴出资及增资以实施募投项目；使用 4.000 万元的募集资金向彭州微芯增资以 实施募投项目；使用 27,920 万元的募集资金向彭州微芯提供借款以实施募投项 目。上述募集资金专项用于实施"彭州微芯原创新药制造基地（一阶段）项目"。 增资完成后，公司对彭州微芯的持股比例仍为 100%。 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意深圳微芯生物科技股份有限 公司向特定对象发行股票注 ...

发行数量和价格 预计上市时间 证券代码：688321 证券简称：微芯生物 公告编号： 2026-016 深圳微芯生物科技股份有限公司 关于向特定对象发行股票发行结果暨股本变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳微芯生物科技股份有限公司（以下简称"公司"或"发行人"）向特定 对象发行股票（以下简称"本次发行"）新增股份 35,133,136 股已于 2026 年 3 月 2 日在中国证券登记结算有限责任公司上海分公司办理完毕股份登记手续。本 次发行新增股份为有限售条件流通股，将在其限售期届满的次一交易日起在上海 证券交易所科创板上市交易，如遇法定节假日或休息日，则顺延至其后的第一个 交易日。 资产过户情况 本次发行的股票全部以现金认购，不涉及资产过户情况。 本次发行对公司股本结构的影响 本次发行不会导致上市公司控制权发生变化，本次发行完成后，上市公司控 股股东、实际控制人仍为 XIANPING LU。 如无特别说明，本公告中涉及有关单位及术语的简称与公司同日在上海证券 交易所网站（htt ...

| 证券代码：688321 | 证券简称：微芯生物 公告编号：2026-017 | | --- | --- | | 转债代码：118012 | 转债简称：微芯转债 | 深圳微芯生物科技股份有限公司 关于因向特定对象发行股票调整"微芯转债"转股价 格暨转股停复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因公司向特定对象发行 A 股股票导致"微芯转债"转股价格调整,本公司的相关证 券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 | 停牌终止 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 期间 | 日 | | | 118012 | 微芯转债 | 可转债转股 | 2026/3/4 | 全天 | 2026/3/4 | 2026/3/5 | | | | 停牌 | | | | | ●调整前转股价格：25.26 元/股 ●调整后转股价格：25.40 元/股 ●转股价格调整实 ...

Group 1 - Ninebot Company achieved a revenue of 21.325 billion yuan in 2025, a year-on-year increase of 50.22%, and a net profit of 1.755 billion yuan, up 61.84% [1] - Huizhong Co., Ltd. reported a revenue of 450 million yuan in 2025, a 16.79% increase, with a net profit of 66.2099 million yuan, up 14.7% [2] - Dalian Heavy Industry achieved a revenue of 15.501 billion yuan in 2025, an 8.54% increase, with a net profit of 588 million yuan, up 18.17% [3] - Jiepte's optical connection business is still in its early stages, contributing less than 5% to total revenue, with uncertainties due to market demand and competition [4] - Yuanguang Software reported a revenue of 2.593 billion yuan in 2025, an 8.12% increase, with a net profit of 301 million yuan, up 2.8% [5] - Kaipu Cloud reported a revenue of 418 million yuan in 2025, a 32.24% decrease, with a net loss of 10.8071 million yuan [6] - Cambricon achieved a total revenue of 6.497 billion yuan in 2025, a 453.21% increase, with a net profit of 2.059 billion yuan, compared to a loss of 452 million yuan in the previous year [7] - Sanxin Medical reported a revenue of 1.64 billion yuan in 2025, a 9.31% increase, with a net profit of 262 million yuan, up 15.43% [8] - Wanji Technology won a project bid worth 22 million yuan, aligning with its smart connected business development plan [9] - Xingrong Environment proposed a cash dividend of approximately 2.35 yuan per 10 shares for 2025, based on a 35% payout ratio of net profit [10] - Lankai Technology achieved a revenue of 5.456 billion yuan in 2025, a 49.94% increase, with a net profit of 2.236 billion yuan, up 58.35% [11] - Muxi Co., Ltd. reported a revenue of 1.644 billion yuan in 2025, a 121.26% increase, but incurred a net loss of 778 million yuan [12] - Hubei Yihua reported a revenue of 25.659 billion yuan in 2025, a 1.04% increase, with a net profit of 889 million yuan, down 16.74% [13] - Microchip Bio proposed a share buyback plan of 80 million to 120 million yuan for employee stock ownership [14] - Moore Thread reported a revenue of 1.506 billion yuan in 2025, a 243.37% increase, with a net loss of 1.024 billion yuan [15] - Huace Navigation achieved a revenue of 3.681 billion yuan in 2025, a 13.24% increase, with a net profit of 681 million yuan, up 16.7% [16] - Jiangfeng Electronics reported a revenue of 4.605 billion yuan in 2025, a 27.75% increase, with a net profit of 481 million yuan, up 20.15% [17] - Wol Nuclear Materials achieved a revenue of 8.451 billion yuan in 2025, a 22% increase, with a net profit of 1.135 billion yuan, up 33.95% [18] - Shenghong Co., Ltd. reported a revenue of 3.463 billion yuan in 2025, a 14.07% increase, with a net profit of 474 million yuan, up 10.58% [19] - Sun Paper achieved a revenue of 39.184 billion yuan in 2025, a 3.79% decrease, with a net profit of 3.258 billion yuan, up 5.05% [20] Group 2 - Wuhan Tianyuan's actual controller plans to reduce holdings by up to 1.93% of the company's shares [21][22] - Zhenghai Bio's shareholder plans to reduce holdings by up to 2% of the company's shares [23] - Baiwei Storage reported a revenue of 11.296 billion yuan in 2025, a 68.72% increase, with a net profit of 867 million yuan, up 437.56% [24] - Jierong Technology received a notice of investigation from the China Securities Regulatory Commission for suspected information disclosure violations [25] - Tengda Construction won a bid for a city parking lot construction project worth 172 million yuan [26] - Jiazhen New Energy's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Jiabiou reported a revenue of 575 million yuan in 2025, a 3.47% increase, with a net profit of 157 million yuan, up 26.15% [28] - Jingsheng Co., Ltd.'s shareholder plans to reduce holdings by up to 3% of the company's shares [29] - Chengdi Xiangjiang's subsidiary signed a significant contract with Shanghai Unicom, with an estimated contract value of 642 million yuan [30] - Guoci Materials plans to acquire 100% of Australian-listed company SDI for 166 million AUD (approximately 816 million yuan) [31] - Zhongfutong plans to raise no more than 643 million yuan through a private placement for various projects [32] - Yuanjie Technology reported a revenue of 601 million yuan in 2025, a 138.5% increase, with a net profit of 191 million yuan, compared to a loss of 6.134 million yuan in the previous year [33] - *ST Dazheng's shareholder plans to reduce holdings by up to 1% of the company's shares [34] - Huasheng Tiancheng clarified its cooperation model with Huawei, indicating that it has a minor impact on overall revenue [35] - Fenghuo Communication reported that its low-orbit satellite communication business contributes less than 1% to total revenue [36] - Huasheng Chang plans to acquire 100% of Jialante's shares for 460 million yuan [37] - Hekang New Energy plans to raise no more than 1.652 billion yuan from Midea Group for various projects [38] - Shuangliang Energy is under investigation by the CSRC for misleading information disclosure [39] - Jingfang Technology reported a revenue of 1.474 billion yuan in 2025, a 30.44% increase, with a net profit of 370 million yuan, up 46.23% [40][41] - Zhongji Xuchuang reported a revenue of 38.24 billion yuan in 2025, a 60.25% increase, with a net profit of 10.799 billion yuan, up 108.81% [42] - Shunluo Electronics reported a revenue of 6.745 billion yuan in 2025, a 14.39% increase, with a net profit of 1.021 billion yuan, up 22.71% [43] - Visual China plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [44] - Haitai Development is under investigation by the CSRC for information disclosure violations [45] - Biyin Lefen's controlling shareholder plans to increase holdings by 100 million to 200 million yuan [46] - Tapa Group reported a revenue of 4.107 billion yuan in 2025, a 3.99% decrease, with a net profit of 634 million yuan, up 17.87% [47] - Lite Optoelectronics plans to invest in a quartz fabric R&D center and production base with a total investment of 1 billion yuan [48] - Demingli reported a revenue of 10.789 billion yuan in 2025, a 126.07% increase, with a net profit of 688 million yuan, up 96.35% [49] - Shengke Communication's state-owned investment fund reduced its shareholding to 13% [50] - Tongxing Technology plans to invest in a sodium-ion battery anode material project with a total investment of approximately 500 million yuan [51] - *ST Rindong applied to revoke the delisting risk warning for its stock, reporting a net profit of 360 million yuan in 2025, compared to a loss of 833 million yuan in the previous year [53] - Guoli Electronics reported a revenue of 1.323 billion yuan in 2025, a 66.98% increase, with a net profit of 70.6089 million yuan, up 133.51% [54] - Jingzhida plans to raise no more than 2.959 billion yuan through a private placement for various projects [55] - Hongdian Film reported a revenue of 2.298 billion yuan in 2025, a 16.55% increase, with a net profit of 159 million yuan, compared to a loss of 96.376 million yuan in the previous year [56] - Jingzhida's shareholders plan to reduce holdings by up to 1.55% of the company's shares [57] - Xin Anjie announced that its chairman is under investigation and has been detained [58]

Core Viewpoint - The chairman of Shenzhen Micu Biotechnology Co., Ltd., Dr. Xianping Lu, proposed a share buyback plan to enhance investor confidence and recognize the company's value, utilizing self-owned and raised funds for the buyback [1][2]. Group 1: Buyback Proposal Details - The proposed buyback will involve the company's issued ordinary shares (A-shares) [2]. - The purpose of the buyback is to support an employee stock ownership plan or equity incentive. Any unutilized repurchased shares within three years will be canceled [2]. - The buyback will be conducted through centralized bidding [2]. - The buyback price will not exceed 150% of the average trading price of the company's shares over the 30 trading days prior to the board's approval of the buyback plan [2]. - The total funds allocated for the buyback will be no less than RMB 80 million and no more than RMB 120 million [2]. - The funding sources for the buyback will be self-owned and raised funds [2]. - The buyback period will be within 12 months from the board's approval of the buyback plan [2]. Group 2: Chairman's Commitment and Trading History - Dr. Xianping Lu has committed to facilitating a board meeting to review the buyback proposal and will vote in favor of the buyback resolution [3]. - There have been no share transactions by Dr. Xianping Lu in the six months prior to the proposal [2].